IMAC (NASDAQ:IMAC) Given “Neutral” Rating at Dawson James

IMAC (NASDAQ:IMAC)‘s stock had its “neutral” rating reissued by equities researchers at Dawson James in a report issued on Tuesday, MarketBeat reports.

Separately, ValuEngine downgraded IMAC from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd.

Shares of IMAC stock traded down $0.03 during midday trading on Tuesday, hitting $1.44. The company had a trading volume of 100 shares, compared to its average volume of 102,493. The company’s 50 day simple moving average is $1.64 and its 200 day simple moving average is $3.00. IMAC has a 52-week low of $1.28 and a 52-week high of $7.20. The company has a current ratio of 0.36, a quick ratio of 0.36 and a debt-to-equity ratio of 0.78.

IMAC (NASDAQ:IMAC) last announced its earnings results on Thursday, November 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.17). IMAC had a negative net margin of 41.07% and a negative return on equity of 114.16%. The company had revenue of $4.36 million during the quarter, compared to analysts’ expectations of $3.97 million. Equities analysts forecast that IMAC will post -0.3 EPS for the current year.

About IMAC

IMAC Holdings, Inc operates a chain of integrated medicine and chiropractic regeneration centers. The company's outpatient clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions.

Featured Story: What is the definition of a trade war?

Receive News & Ratings for IMAC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMAC and related companies with MarketBeat.com's FREE daily email newsletter.